Summary: The Soulspace Podcast speaks with clinical psychologist and psychedelic researcher Anne Wagner, Ph.D., about how PTSD impacts relationships. Wagner shares her experience working on the MAPS-sponsored trial of MDMA-assisted cognitive-behavioral conjoint psychotherapy for PTSD, which aims to study therapeutic benefits for a participant with PTSD and their significant other.
Originally appearing here.
As the so-called third wave of psychedelic renaissance unfolds, the notion of self-improvement has taken a new and deeper meaning. After a long slumber, the field of mental health is waking up to the therapeutic potentialities of these powerful tools in relieving symptoms of depression, PTSD, addiction, and fear surrounding terminal illness. Targeted towards beginners, Michael Pollen’s book How To Change Your Mind, published in the summer of 2018, propelled the conversation around psychedelics to the forefront. Whether it is MDMA, LSD, psilocybin, ayahuasca, or others, the potential for consciousness expansion and psycho-spiritual growth is immense.
The FDA recently granted “Breakthrough Therapy” Designation to MDMA for the treatment of post-traumatic stress disorder (PTSD) and is currently in phase 3 clinical trials. Popularly known as a recreational drug, and as the main ingredient in ecstasy, MDMA is paving the way for the possible near-term legalization of psychedelic therapy.
On this episode, we talk to Anne Wagner, a clinical psychologist and one of the lead investigators involved in the MAPS funded clinical trials of MDMA + cognitive-based psychotherapy for PTSD. Anne tells us how she ended up working in the cutting edge of psychedelic science and what these studies offer for the future of mental health. In her clinical practice, Anne applies a cognitive-behavioural and mindfulness-based approach to therapy and she also offers preparation and integration of psychedelic and non-ordinary state experiences. We got to connect with Anne at her new clinic, Remedy in Toronto.